HO-3867, a Safe STAT3 Inhibitor, Is Selectively Cytotoxic to Ovarian Cancer

Kellie S. Rath¹, Shan K. Naidu¹, Pushpa Lata¹, Hemant K. Bid², Brian K. Rivera¹, Georgia A. McCann¹, Brent J. Tierney¹, Adam C. ElNaggar¹, Veronica Bravo³, Gustavo Leone³, Peter Houghton², Kálman Hideg⁵, Periannan Kuppusamy⁴, David E. Cohn¹, and Karuppaiyah Selvendiran¹

Abstract

STAT3 is well corroborated preclinically as a cancer therapeutic target, but tractable translational strategies for its blockade by small molecule inhibitors have remained elusive. In this study, we report the development of a novel class of bifunctional STAT3 inhibitors, based on conjugation of a diarylidenyl-piperidone (DAP) backbone to an N-hydroxybenzyl (NOH) group, which exhibits minimal toxicity against normal cells and good oral bioavailability. Molecular modeling studies of this class suggested direct interaction with the STAT3 DNA binding domain. In particular, the DAP compound HO-3867 selectively inhibited STAT3 phosphorylation, transcription, and DNA binding without affecting the expression of other active STATs. HO-3867 exhibited minimal toxicity toward noncancerous cells and tissues but induced apoptosis in ovarian cancer cells. Pharmacologic analysis revealed greater bioabsorption and bioavailability of the active (cytotoxic) metabolites in cancer cells compared with normal cells. The selective cytotoxicity of HO-3867 seemed to be multifaceted, eliciting differential activation of the Akt pathway in normal versus cancer cells. RNAi attenuation experiments confirmed the requirement of STAT3 for HO-3867–mediated apoptosis in ovarian cancer cells. In vivo testing showed that HO-3867 could block xenograft tumor growth without toxic side effects. Furthermore, in primary human ovarian cancer cells isolated from patient ascites, HO-3867 inhibited cell migration/invasion and survival. Our results offer preclinical proof-of-concept for HO-3867 as a selective STAT3 inhibitor to treat ovarian cancer and other solid tumors where STAT3 is widely upregulated. Cancer Res; 74(8): 1–12. ©2014 AACR.

Introduction

The toxic side effects that standard anticancer drugs exert on healthy tissues and normal cells present obstacles in cancer treatment. These effects lead to dose reductions, treatment delays, and even the discontinuation of therapy. “Targeted therapy” is a relatively modern term commonly used to describe new agents, including small molecules and monoclonal antibodies, specifically designed to take advantage of molecular pathways involved in the pathophysiology to be treated. A secondary goal of such developments is to limit the negative side effects these molecules exert on normal tissues. Unfortunately, even new therapeutics cause significant adverse effects on normal tissues, leading to toxicity. Thus, development of safe and targeted anticancer therapies that selectively kill cancer cells while sparing the surrounding healthy tissues is essential.

We identified a novel class of bifunctional compounds based on a diarylidenyl-piperidone (DAP) backbone conjugated to an N-hydroxybenzyl (NOH; a nitroxide precursor) group for their inhibitory property on STAT3 activation (1, 2). Previous work found that DAP compounds exhibit more toxicity toward cancer cells when compared with noncancerous cells. However, the mechanism behind this selectivity was not fully elucidated. We hypothesize that the addition of the −NOH moiety functions as a modulator of cytotoxicity, imparting antioxidant protection to noncancerous tissues, while allowing the compound to maintain toxicity toward cancer cells. Two compounds, HO-3867 (possessing the −NOH moiety) and H-4073 (lacking the −NOH moiety) with the same DAP backbone were used to expound upon this concept (1, 3–5). In this study, we confirm the selective toxicity of HO-3867 as compared with H-4073. The mechanism of this selectivity is a differential interaction of HO-3867 and H-4073 with STAT3 in normal and cancer cells, with no impact upon other STATs. In addition, both compounds exhibit greater uptake and bioavailability in cancer cells when compared with normal cells. HO-3867 demonstrated anticancer efficacy in both a...
xenograft model and cisplatin-sensitive and cisplatin-resistant primary ovarian cancer cell populations. These results support the translational potential for HO-3867 as a safe, targeted compound for the treatment of ovarian cancer.

Materials and Methods

Transfection of cells with pBOS-H2BGFP vector and chromatin aberration assay

A2780 and CHO cells were plated 1 day before and were
~80% confluent on the day of transfection. Cells were trans-
ferred with pBOS-H2BGFP vector DNA (1 μg/μL; BD Pharmin-
gen) using FuGene 6 transfection reagent according to man-
ufacturer’s instructions.

STAT3 DNA-binding assays

After treatment with HO-3867 for 24 hours, a Nuclear Extract Kit (Clontech Inc.) was used to prepare cell nuclear extracts following the manufacturer’s protocol (6, 7).

STAT3 knockdown experiments

For downregulation of STAT3 in SKOV3 cells, a lentiviral system (pGIPZ) with a set of different short hairpin RNAs (shRNA) was used (Thermo Scientific). A scrambled shRNA was used as a control.

Statistical analysis

Results are expressed as mean ± SE. Comparisons between
groups were made by the Student t test and ANOVA as
appropriate. The significance level was set at P < 0.05. Prism
Graph Pad was used for all statistical calculations.

Results

DAPs target STAT3

A new class of DAP compounds was synthesized by linking
two diarylidene groups with a piperidone group; an antioxi-
dant-promoting N-hydroxyproline moiety was attached to
the piperidone N-terminal of the base compound H-4073
to obtain HO-3867 (Fig. 1A). Treatment of SKOV3 cells with
different concentrations of HO-3867 and H-4073 resulted
in significantly decreased expression of pSTAT3 (Fig. 1B). DAP
compounds exhibited the highest binding affinity for a pocket
located on the DNA-binding domain of the STAT3 molecule
(Fig. 1C). This is in contrast to other known STAT3 inhibitors,
many of which interact with STAT3 at the SH2 domain (8–10).
In addition, HO-3867 interacts with both the STAT3 dimer
and monomer structures (Fig. 1D). H-4073 docked with the STAT3
monomer is shown in Supplementary Fig. S1A.

Western blots demonstrate that HO-3867 does not impact
expression of other pSTATs (Fig. 1E). Because in silico docking
simulations suggested that the compounds interact with the
DNA-binding domain of STAT3, we evaluated this in vitro.
SKOV3 cells were treated with 10 μmol/L of H-4073 or HO-
3867, and samples subjected to ELISA assay. DNA binding
activity was measured, and both compounds inhibited STAT3
DNA binding activity when compared with control (Fig. 1F).

Additional mechanistic studies focused upon HO-3867,
which was indicated to have the greater binding affinity than
H-4073 for the STAT3 DNA-binding domain. The difference in
binding affinity is believed to be because of the inclusion of the
–NOH moiety in the HO-3867 structure. Purified STAT3 pro-
tein (2 μg) was incubated with HO-3867 (10 μmol/L) for 2
hours. STAT3 was immunoprecipitated, repeatedly washed to
remove unbound HO-3867, and subjected to electron par-
magnetic resonance (EPR) analysis at X-band (9.8 GHz). As
shown in Fig. 1G, a clear triplet EPR signal, characteristic of
nitroxide (–NO) compounds, was obtained from human
STAT3 incubated with HO-3867, suggesting DAP-STAT3
interaction. Figure 1H shows a reduction in luciferase expres-
sion when the cells were treated with HO-3867, whereas no
change in STAT4 and STAT5 transcriptional activity was
observed. Mechanistically, STAT3 nuclear translocation was
examined using a previously reported method (10, 11). A2780
cells were treated for 3 hours with 10 μmol/L of HO-3867, after
which STAT3 translocation was stimulated by adding IL-6 for 30
minutes. As shown in Fig. 1I, STAT3 nuclear translocation in
the HO-3867–treated cells was inhibited (right) when com-
pared IL-6–stimulated cells. The intensity of nuclear pSTAT3
staining was quantified from the green channel. Treatment
with HO-3867 reduced overall pSTAT3 expression and nuclear
expression of pSTAT3 when compared with control or IL-6
stimulated cells (Supplementary Fig. S1B). These results pro-
vide evidence that DAP compounds interact specifically with
STAT3 and inhibit its binding to DNA by preventing dimer-
ization, nuclear translocation and/or phosphorylation.

Effect of DAPs on cancer cells versus normal cells

Development of STAT3 inhibitors that are selectively cyto-
toxic to cancer cells while sparing normal cells would be a
significant step forward in cancer therapeutics. We hypothe-
size that the –NOH moiety of HO-3867 serves as a modulator of
cytotoxicity. H-4073, which possesses an identical backbone
structure but lacks the –NOH antioxidant precursor group, was
used for comparative purposes. Both DAP compounds inhib-
ited proliferation in ovarian cancer cells in a dose- and time-
dependent manner. However, HO-3867 exhibited minimal
toxicity toward normal cells, whereas H-4073 was toxic to
both cell types (Supplementary Fig. S2A and S2B). Clonogenic
assays confirm that HO-3867 is less toxic to normal CHO
when compared with H-4073 (22% vs. 92%, P < 0.05; Fig.
2A and B).

Successful transfection of the A2780 and CHO cells with
GFP-Histone 2B fusion protein was confirmed by fluorescence-
activated cell sorting (FACS; Supplementary Fig. S3). Trans-
ferred cells were treated with 10 μmol/L of HO-3867 or H-4073
for up to 24 hours, followed by immunofluorescence micros-
copy. In Fig. 2C, red arrows indicate individual cells that
underwent abortive mitosis with transient chromatin conden-
sation or apoptosis. Quantification of chromosomal aberration
at different time points (means ± SEM, n = 100 cells/data
point), confirms the differential action of HO-3867 on normal
versus cancer cells, P < 0.0001 (Fig. 2D). Using flow cytometry,
apoptosis was quantified in A2780, hOSE, CHO, and H9c2 cells
treated with 10 μmol/L of HO-3867 or H-4073 for 24 hours.
HO-3867 induced less apoptosis in hOSE, CHO, and H9c2 cells
when compared with A2780 cells (12.3% vs. 55.8%, P < 0.0001),
respectively, whereas H-4073 induces apoptosis in both cell types (63.6% vs. 48.5%, \(P < 0.0001\); Supplementary Table S1 and Fig. S4A and S4B). When compared with other STAT3 inhibitors HO-3867 show similar toxicity to cancer cells, but decreased toxicity to normal cells (Supplementary Fig. S5). Furthermore, we evaluated oxidative stress in the cells using 8-hydroxyguanosine (8OHdG) after treating cells with HO-3867 or H-4073 for 6 hours. After treatment with H-4073, both cell lines showed similar of levels of 8OHdG. Conversely, HO-3867 treatment resulted in elevated 8OHdG staining in cancer cells relative to normal cells (Fig. 2E). Based on our previous report (2), which showed that DAP compounds induce apoptosis via activation of caspase-3 in cancer cells, we examined the expression level of caspase-3 activity in both hOSE and A2780 cells treated with 10 \(\mu\)mol/L of HO-3867 or H-4073. An increase in caspase-3 activity expression was found in HO-3867–treated ovarian cancer cells when compared with HO-3867–treated normal cells and untreated controls, but no difference was observed after H-4073 treatment (Fig. 2F). This suggests a differential involvement of caspase-3 in HO-3867–induced apoptosis. It is clear that although HO-3867 and H-4073 show similar toxicity toward cancer cells, H-4073 is significantly more toxic toward normal cell types.

Differential bioabsorption of DAPs in ovarian cancer cells versus normal cells

To evaluate the mechanism behind the differential toxicity exhibited by the 2 compounds, we used EPR spectroscopy, UV/Vis spectrophotometry, and liquid chromatography/mass
spectrometry (LC/MS) with both CHO or hOSE cells and A2780 cells (3). For the EPR study, hOSE and A2780 cells were treated with HO-3867 at 10 μmol/L for 3 hours, and then collected for analysis. The N-hydroxyproline (–NOH) moiety is capable of undergoing a reversible, one-electron oxidation to its nitroxide form (–NO), which is paramagnetic and detectable by EPR spectroscopy (12). A substantial amount of the nitroxide form of HO-3867 was detected in both cells using EPR, suggesting that HO-3867 rapidly entered the cells during the 3 hour exposure period (Fig. 3A).
The difference in signal amplitude observed in Fig. 3A would, at first, seem counterintuitive. It would be expected that a lower concentration of the nitroxide form would be found in the cancer cells, which have a more reductive environment than the corresponding normal cells, thereby producing lower signal amplitude. To further evaluate this, we quantified the cellular uptake of both H-4073 and HO-3867 at the same dose (10 μmol/L) and time point in both cells using UV/Vis spectroscopy. The cellular uptake of HO-3867 was 5-fold and H-4073 was 2-fold greater in cancer cells than in normal cells after 3 hours of incubation (Fig. 3B). Uptake of HO-3867 by CHO and A2780 cell lines was also analyzed by a liquid chromatography and tandem mass spectrometry (LC-MS/MS) assay. Both cell lines were treated with 10 μmol/L of either HO-3867 or H-4073, and cells were harvested at the allocated time points of 0, 1, 3 and 6 hours. Drug concentration was measured and calculated against the calibration curve of HO-3867. A2780 cells showed significant uptake of HO-3867, but CHO cells had no detectable levels of HO-3867 (Fig. 3C) and lower levels of H-4073 when compared with A2780 cells (Supplementary Fig. S6A). These results help to explain the greater EPR signal amplitude from the cancer cells. Despite the more reductive environment, a greater concentration of HO-3867 molecules, in both forms, would be present in the cancer cells, thereby providing a greater signal when compared with the noncancerous cells.

Next, in vitro metabolism studies were completed. In both A2780 and CHO cell lines, the major metabolite observed following incubation was the M+4 metabolite (Supplementary Table S2). The concentration, as represented by the response area of the M+4 metabolite, is much higher in CHO in comparison to A2780 cells for both compounds (Fig. 3D and E). This suggests that CHO cells metabolize HO-3867 faster than H-4073, which may explain why no HO-3867 was detected in the CHO cells by EPR spectroscopy. Extracted ion chromatograms of metabolites following exposure to H-4073 or HO-3867 in both CHO and A2780 cells at different time points were obtained (Supplementary Fig. S6B–S6E).

**Differential effect of HO-3867 on STAT3/Akt signaling pathway in cancer cells versus normal cells**

The differential bio-absorption study results obtained using EPR and LC/MS do not fully explain the selective mechanism of action of HO-3867. To elucidate this further, we examined the effect of HO-3867 on the STAT3/Akt signaling pathway, specifically looking at STAT3 activation and STAT3-mediated genes. After treatment of A2780 and SKOV3 cells with 10 μmol/L of HO-3867, analysis showed decreased levels of p-STAT3, p-Akt Ser473, and Bcl-2, with a concomitant increase in p-STAT3, p53, or Bcl-2 levels, but an increase in pAkt Ser473 (Fig. 4A and B). This suggests that activation of pAkt in normal cells protects them from apoptosis, whereas inhibition of pSTAT3 and pAkt in HO-3867-treated A2780 or SKOV3 cells, promotes apoptosis. Changes in phosphorylated Akt expression were confirmed by confocal microscopy, as shown in Fig. 4C. Conversely, treatment with H-4073 showed decreased levels of pSTAT3 and elevated cleaved-caspase-7 in both CHO and A2780 cells (Supplementary Fig. S7A).

**Akt siRNA reverses the selective cytotoxicity of HO-3867 in CHO cells**

Akt siRNA was transfected into CHO cells for 24 hours to determine if the apparent selective activation of Akt is necessary for HO-3867–mediated cytotoxicity. Cells were treated with 10 μmol/L of HO-3867 for 24 hours. Western blot analysis confirmed transfection. In CHO cells transfected with Akt siRNA before treatment with HO-3867, lower levels of total Akt and pAkt were observed when compared with untransfected controls. This decrease in pAkt resulted in an increase in the apoptosis markers cleaved-caspase-7 and cleaved-PARP (Fig. 4D). Decreased viability and doubling of the number of cells undergoing apoptosis was observed in transfected cells treated with HO-3867 (Fig. 4E and F). This indicates that activation of Akt is essential in the reduced cytotoxicity of HO-3867 in normal cells. Next, we sought to determine if the selective activation or inhibition of pAkt was because of alterations in kinase pathways induced by HO-3867. Akt kinase activity was evaluated after treatment with HO-3867, and activation or suppression of various kinases was noted in A2780 (Fig. 4G) but not CHO cells (Supplementary Fig. S7B). This suggests that the selective toxicity exhibited by HO-3867 is related to differential effects on the STAT3/Akt pathway in ovarian cancer cells. Further study is required in other cell lines to confirm the activation of Akt by HO-3867 in noncancerous cell lines.

**Effect of HO-3867 treatment on STAT3 knockdown ovarian cancer cells**

To investigate the requirement of STAT3 in HO-3867–mediated apoptosis, we knocked down STAT3 in ovarian cancer cells using shRNA. Western blot analysis confirmed knockdown. (Fig. 5A). STAT3 knockdown cells were treated with 10 μmol/L of HO-3867 for 24 hours, then cell viability and apoptosis were analyzed. Among SKOV3 STAT3 knockdown cells, viability was increased (Fig. 5B) with a 50% reduction of apoptosis following treatment with HO-3867 when compared with wild-type cells (Fig. 5C and D). These results confirm that HO-3867 inhibition of cell proliferation and induction of apoptosis is mediated primarily by targeting the STAT3 pathway.
HO-3867 selectively targets STAT3 and Akt expression in cancer cells. A and B, immunoblot of hOSE, SKOV3, A2780, and CHO cells treated with 10 μmol/L of HO-3867 for 24 hours. C, confocal microscopy showing pAkt Ser473 expression in hOSE and SKOV3 cells before and after treatment with 10 μmol/L of HO-3867 for 24 hours. Treatment increased pAkt Ser473 in hOSE cells, but inhibited it in SKOV3 cells. D, Akt siRNA was used to silence Akt in CHO cells. Cells were then treated with 10 μmol/L of HO-3867 for 24 hours. Immunoblot analysis was used to evaluate Akt, pAkt Ser473, cleaved-caspase-7, and cleaved-PARP. E, cell viability was decreased in CHO cells transfected with Akt siRNA and treated with HO-3867 when compared with other groups \( (P < 0.05) \). F, Annexin V performed using CHO cells: control, Akt siRNA alone, 10 μmol/L of HO-3867 alone, and combination. Increased apoptosis was observed in CHO cells transfected with Akt siRNA and treated with 10 μmol/L of HO-3867 for 24 hours when compared with all other groups \( (\ast, P < 0.05, n = 6) \). G, protein kinase array performed on SKOV3 cells with and without 10 μmol/L of HO-3867 treatment for 24 hours.

**Figure 4.** HO-3867 selectively inhibits STAT3 and Akt expression in cancer cells. A and B, immunoblot of hOSE, SKOV3, A2780, and CHO cells treated with 10 μmol/L of HO-3867 for 24 hours. C, confocal microscopy showing pAkt Ser473 expression in hOSE and SKOV3 cells before and after treatment with 10 μmol/L of HO-3867 for 24 hours. Treatment increased pAkt Ser473 in hOSE cells, but inhibited it in SKOV3 cells. D, Akt siRNA was used to silence Akt in CHO cells. Cells were then treated with 10 μmol/L of HO-3867 for 24 hours. Immunoblot analysis was used to evaluate Akt, pAkt Ser473, cleaved-caspase-7, and cleaved-PARP. E, cell viability was decreased in CHO cells transfected with Akt siRNA and treated with HO-3867 when compared with other groups \( (P < 0.05) \). F, Annexin V performed using CHO cells: control, Akt siRNA alone, 10 μmol/L of HO-3867 alone, and combination. Increased apoptosis was observed in CHO cells transfected with Akt siRNA and treated with 10 μmol/L of HO-3867 for 24 hours when compared with all other groups \( (\ast, P < 0.05, n = 6) \). G, protein kinase array performed on SKOV3 cells with and without 10 μmol/L of HO-3867 treatment for 24 hours.

**HO-3867 inhibits xenograft tumor growth without toxicity to other tissues in tumor-bearing mice**

We evaluated the efficacy of HO-3867 in a chemotherapy-resistant human ovarian tumor model; mice were injected with A2780cDDP cells. After 28 days, the feed was supplemented with 2 concentrations of HO-3867 (50 or 100 ppm; Harlan-Teklad). Treated mice showed significant reductions in tumor mass, in a dose-dependent manner. Images of tumor bearing control and HO-3867-treated (100 ppm) mice are shown in Fig. 6A, with a graph showing the tumor weight at the time of tissue collection (Fig. 6B, top half). There was no decrease in body weight, a common side effect of traditional chemotherapy.
Excised tumor tissue from HO-3867 treated mice showed decreased levels of STAT3 Tyr705 and Bcl-2 levels, without affecting total STAT3 (Fig. 6C and Supplementary Fig. S8). To confirm uptake of HO-3867, tumor tissues and organs from HO-3867 treated and untreated mice were collected and prepared for EPR spectroscopic analysis as described previously (12). Clear, triplet signals indicating the presence of the \(-\text{NO}/C_1\) radical (nitroxide) form of HO-3867 were obtained from liver, ovary, kidney, and spleen tissues. Brain, heart, and lung tissues seem to produce possible, but extremely weak signals (Supplementary Fig. S9). In addition, HO-3867 uptake by the tumor tissues was quantified using UV/Vis spectroscopy (Fig. 6D).

The toxicity of HO-3867 in various organs and tumor tissues was evaluated using hematoxylin and eosin (H&E) and terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling (TUNEL) staining. H&E staining showed increased necrosis in tumors of HO-3867–treated mice when compared with control (Fig. 6E). No evidence of any cellular degeneration or inflammatory lesions was observed in mice supplemented with HO-3867 (Supplementary Fig. 10A). The results did not reveal increased apoptosis in the normal organ tissues of animals treated with HO-3867, however there was marked TUNEL-positive staining in tumor tissues treated with HO-3867 when compared with untreated controls (Fig. 6F and G and Supplementary Fig. S10B). These results confirm the efficacy of HO-3867 against chemoresistant ovarian tumors, with no apparent signs of toxicity toward normal tissues. The data show that HO-3867 inhibits ovarian cancer by targeting the STAT3 signaling pathway.

**Ex vivo efficacy of HO-3867 on primary ovarian cancer cell populations**

The efficacy of HO-3867 was evaluated in primary ovarian cancer populations using cell lines TR-127 and TR-182 (Dr. G. Mor, Yale University) derived from recurrent, chemotherapy-
resistant tissues, and one collected from the ascites of a patient at The Ohio State University Wexner Medical Center. We found consistent expression of active STAT3 in primary cancer cell populations (Fig. 7A). Treatment with HO-3867 inhibited cell survival (Fig. 7B) and induced more cell death within 24 hours when compared with STATTC and standard anticancer drugs.
(Supplementary Fig. S11A–S11C). Expression of STAT3, pAkt, and STAT3 target proteins cyclin D1, cyclin D2, and survivin was decreased after treatment with HO-3867 (Supplementary Fig. S12). Tumor cells in ascites are a major source of metastasis and disease recurrence in ovarian cancer patients. In vitro migration (Fig. 7C and D) and invasion (Fig. 7E and F) of these cells lines were inhibited by HO-3867. These results show that HO-3867 demonstrates anticancer efficacy in ovarian cancer.

Figure 7. HO-3867 inhibits migration and invasion, and is cytotoxic to primary ovarian cancer cells. A, STAT3 expression in primary ovarian cell populations. B, three different primary ovarian cancer cell lines were treated with 5 or 10 μmol/L of HO-3867 for 24 hours and subjected to clonogenic assay. Quantification of clonogenic survival in cells showing decreased, dose-dependent survival in all cell lines when compared with control (n = 3, reported % ± SEM, P < 0.0001 all groups vs. control). C, cell migration/wound healing assay representative images using primary ovarian cell lines evaluated before and after 24 hours exposure to 10 μmol/L of HO-3867 with corresponding controls. D, the residual gap between the migrating cells from the opposing edges is expressed as a percentage of the initial, scraped area. HO-3867 significantly inhibits the reduction in gap size caused by cell migration (n = 5, control, treated, mean ± SD; all *, P < 0.0001). E, representative images of the invasion assay results using a transwell Boyden chamber with primary ovarian cancer cell lines and corresponding controls. F, quantification of invasion assay. HO-3867 inhibits invasion versus control in all cell lines (n = 3, mean ± SD; *, n = 3, P < 0.0001).
cells, xenografts, and primary cell populations, suggesting the translational potential for HO-3867 as a safe, targeted compound for the treatment of ovarian cancer.

Discussion

Drug development is a long and arduous journey. Many compounds are developed and evaluated on a yearly basis to find a promising few that are suitable for human clinical trials. Our compound, HO-3867, shows great promise in preclinical evaluations for the treatment of ovarian cancer. It has shown toxicity toward recurrent primary ovarian cancer cell populations, excellent oral bio-absorption, and bio-availability in a xenograft model, as well as in vivo toxicity in platinum-resistant tumors. However, many compounds have these properties—the novel innovation that sets HO-3867 apart is its selective toxicity toward cancer cells while sparing normal cells in both in vitro and in vivo experiments by taking advantage of one of the underlying biomolecular causes of disease.

At present, only a few agents are known to possess the potential for selective/preferential elimination of cancer cells without affecting normal cells (13–15). Sanguinarine, an alkaloid derived from the root of Sanguinaria canadensis and used commonly in mouth washes and toothpaste is one such compound. In vitro data show that it displays toxicity toward human epidermoid carcinoma (A431) cells but not normal human epidermal keratinocytes (16).

In this study, we were able to elucidate the mechanism behind the selective toxicity of HO-3867 and translate this to an in vivo model showing little or no toxicity at clinically effective doses. The mechanism is multifaceted, but is based on the addition of the N-hydroxy-2-pyrrolidine (−NOH) moiety to H-4073, to obtain HO-3867. This moiety functions as a modulator of cytotoxicity, allowing the compound to exist in an equilibrium of oxidized (−NO) and reduced forms (−NOH) depending on the cellular environment (17). In normal cells, the N-hydroxy-2-pyrrolidine group has the greater potential to oxidize, generating a nitroxide that imparts antioxidant protection to noncancerous tissues (17–20). In cancer cells and hypoxic tumors, the microenvironment is far more reductive in nature, inhibiting oxidation and reducing antioxidant protection to tumor cells (21–23).

The difference between oxidized and reduced forms of nitroxyl radicals has been well established using EPR (24–26). Previous (1) and current study from our lab revealed that after in vitro treatment with HO-3867, cancer cells have higher levels of reactive oxygen species (ROS) and elevated 8OHdG expression when compared with normal cells as measured by DHE and 8OHdG staining. This suggests that HO-3867 acts as an antioxidant in normal cells, but not in cancer cells. In this study, we show that the bio-absorption of HO-3867 is greater in cancer cells and more slowly metabolized, which likely contributes to the enhanced toxicity; allowing greater accumulation of ROS. This is in contrast to platinum-based chemotherapeutic agents, which promote ROS accumulation in both cancer and normal cells, leading to significant systemic toxicity. A previous study found that mice cotreated with cisplatin and HO-3867 did not have a reduction in body weight compared with control, whereas those treated with the same dose of cisplatin alone did lose weight during treatment (27). Given these findings it is possible that combining cisplatin with HO-3867 may protect against cisplatin-associated nephrotoxicity.

Another facet to the selective toxicity is a differential impact at the molecular level. HO-3867 preferentially inhibits phosphorylation of STAT3, and to a lesser extent Akt, in cancer cells, but activates Akt expression in normal cells. This leads to selective cell killing of cancer cells while protecting normal cells. This is congruent with previous work from our lab, showing that cotreatment with HO-3867 and doxorubicin prevents development of doxorubicin-associated cardiomyopathy in mice through a similar mechanism (4). These data establish a critical and unique dependency on Akt activation for the protection of normal cells and inhibition of STAT3 activation for anticancer effect.

To our knowledge, this is the first systematic study showing the selective induction of apoptosis in ovarian cancer cells versus normal cells using an orally deliverable STAT3 inhibitor. Most importantly, we show that HO-3867 is highly effective in primary cancer cell populations, including cells known to be resistant to conventional chemotherapeutics. Viable treatment options for this latter cancer cell type are currently very limited or unavailable, suggesting potential translational application of HO-3867 for the safe treatment of ovarian cancer, including recurrent disease. However, additional studies are needed to confirm the selective cytotoxicity of HO-3867 via Akt signaling mechanisms in vivo. Safe and targeted inhibitors are an essential tool for future therapeutic intervention, particularly in the treatment of cancers. The present results provide a convincing argument for preclinical evaluation of HO-3867 in the treatment of ovarian cancer, including cancer that has developed resistance to conventional chemotherapeutic intervention.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions


Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): K.S. Rath, S.K. Naidu, P. Lata, B.H. Hemant, G.A. McCann, B.J. Tierney, A.C. ELNagger, K. Hideg


Writing, review, and/or revision of the manuscript: K.S. Rath, S.K. Naidu, B.H. Hemant, B.K. Rivera, G.A. McCann, A.C. ELNagger, P. Houghton, K. Hideg, P. Kuppusamy, D.E. Cohn, K. Selvendiran

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): B.H. Hemant, B.K. Rivera, G.A. McCann, B.J. Tierney, G. Leone, K. Hideg

Study supervision: K. Hideg, D.E. Cohn, K. Selvendiran

Acknowledgments

The authors thank Drs. P. Goodfellow, J. Hays, and B. Kaur for their valuable insights, comments, and suggestions in the construction of this article; Dr. M. Phelps and Dr. Y. Ling of the Pharmacological Shared Resource for LC/MS analysis; and Dr. G. Mor of Yale University for providing the primary ovarian cancer cell populations. The authors also thank graduate students Ross Wanner, Meryl Sudhakar, and Priya Nalluri for the cell culture and basic assay help.
Grant Support
This work was supported by Ovarian Cancer Research Fund (OCRF) and Kaleidoscope of Hope foundation awards to K. Selvendiran and OSU CCC Internal grant to D.E. Cohn.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 23, 2013; revised January 28, 2014; accepted January 31, 2014; published OnlineFirst March 3, 2014.

References


HO-3867, a Safe STAT3 Inhibitor, Is Selectively Cytotoxic to Ovarian Cancer


Cancer Res  Published OnlineFirst March 3, 2014.

Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-13-2433

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2014/03/04/0008-5472.CAN-13-2433.DC1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.